Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

DCPH

Deciphera Pharmaceuticals Inc

Jun 10 • 04:00PM ET

25.59

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF VTWO VHT VTWV VTWG VTHR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.21	Insider Own	35.44%	Shs Outstand	80.50M	Perf Week	0.12%
Market Cap	2.21B	Forward P/E	-	EPS next Y	-1.51	Insider Trans	-0.06%	Shs Float	55.83M	Perf Month	0.87%
Income	-190.42M	PEG	-	EPS next Q	-0.51	Inst Own	61.99%	Short Float	5.68%	Perf Quarter	54.72%
Sales	174.91M	P/S	12.65	EPS this Y	12.69%	Inst Trans	1.28%	Short Ratio	1.71	Perf Half Y	69.81%
Book/sh	3.85	P/B	6.65	EPS next Y	24.70%	ROA	-39.26%	Short Interest	3.17M	Perf Year	83.05%
Cash/sh	3.15	P/C	8.12	EPS next 5Y	21.00%	ROE	-50.37%	52W Range	9.90 - 25.61	Perf YTD	58.65%
Dividend Est.	-	P/FCF	-	EPS past 5Y	4.07%	ROI	-56.42%	52W High	-0.08%	Beta	0.20
Dividend TTM	-	Quick Ratio	3.94	Sales past 5Y	51.62%	Gross Margin	93.26%	52W Low	158.48%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	4.19	EPS Y/Y TTM	5.92%	Oper. Margin	-118.09%	RSI (14)	85.58	Volatility	0.13% 0.17%
Employees	355	Debt/Eq	0.08	Sales Y/Y TTM	26.51%	Profit Margin	-108.86%	Recom	2.75	Target Price	26.34
Option/Short	Yes / No	LT Debt/Eq	0.07	EPS Q/Q	14.02%	Payout	-	Rel Volume	0.00	Prev Close	25.59
Sales Surprise	-0.31%	EPS Surprise	6.42%	Sales Q/Q	34.55%	Earnings	May 01	Avg Volume	1.85M	Price	25.59
SMA20	0.32%	SMA50	20.33%	SMA200	61.93%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Resumed	JP Morgan	Neutral	$14
Oct-30-23	Upgrade	Piper Sandler	Neutral → Overweight	$23
Aug-10-23	Upgrade	Stifel	Hold → Buy	$14 → $20
Jan-04-23	Upgrade	Guggenheim	Neutral → Buy	$22
Aug-29-22	Initiated	Cowen	Outperform	$25
Aug-05-22	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$23
Feb-28-22	Downgrade	Barclays	Equal Weight → Underweight	$11 → $6
Nov-08-21	Downgrade	Stifel	Buy → Hold	$60 → $10
Nov-08-21	Downgrade	Canaccord Genuity	Buy → Hold	$72 → $12
Nov-08-21	Downgrade	Barclays	Overweight → Equal Weight	$50 → $11
Nov-05-21	Downgrade	Truist	Buy → Hold	$65 → $10
Sep-30-21	Resumed	Stifel	Buy	$60
Mar-31-21	Initiated	Credit Suisse	Outperform	$78
Feb-10-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$70
Dec-03-20	Initiated	Stifel	Buy	$75
Sep-14-20	Resumed	JP Morgan	Neutral	$52
May-07-20	Downgrade	Nomura	Buy → Neutral	$84 → $60
Mar-04-20	Initiated	Barclays	Overweight	$70
Dec-20-19	Reiterated	Jefferies	Buy	$53 → $77
Oct-29-19	Upgrade	SVB Leerink	Underperform → Mkt Perform	$29 → $34

Show Previous Ratings

Jun-11-24 08:30AM	Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono) (PR Newswire)
Jun-03-24 07:00AM	Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet (Business Wire)
May-23-24 01:15PM	Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why (Zacks)
May-10-24 01:54PM	DCPH Stock Earnings: Deciphera Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
09:30AM	Here's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings (Zacks)
08:50AM	Loading…
08:50AM	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Apr-30-24 07:10AM	Barclays Upgrades Deciphera Pharmaceuticals to Equalweight From Underweight, Price Target is $26 (MT Newswires)
07:03AM	Leerink Downgrades Deciphera Pharmaceuticals to Market Perform, Price Target at $25.60 (MT Newswires)
07:02AM	JMP Downgrades Deciphera Pharmaceuticals to Market Perform (MT Newswires)
07:00AM	ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals (PR Newswire)
03:41AM	Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion (Reuters)
Apr-29-24 02:36PM	Top Midday Gainers (MT Newswires) +72.56%
02:17PM	Why Is Cancer Focused Deciphera Pharmaceuticals Stock Skyrocketing On Monday? (Benzinga)
01:41PM	Sector Update: Health Care (MT Newswires)
01:02PM	Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn (Pharmaceutical Technology)
12:17PM	Loading…
12:17PM	JonesTrading Downgrades Deciphera Pharmaceuticals to Hold From Buy, Adjusts Price Target to $25.60 From $16 (MT Newswires)
12:16PM	Deciphera Agrees to $2.4 Billion Buyout Offer From Japan's ONO Pharmaceutical (MT Newswires)
11:19AM	Jefferies Downgrades Deciphera Pharmaceuticals to Hold From Buy, Trims Price Target to $25.60 From $26 (MT Newswires)
10:46AM	Citi Just Raised Its Price Target on Shopify (SHOP) Stock (InvestorPlace)
10:33AM	Why Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today? (InvestorPlace)
09:57AM	Deciphera Pharmaceuticals Is Being Acquired and the Stock Soars 72% (Barrons.com)
09:02AM	Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday (MT Newswires)
08:54AM	Update: Deciphera Pharmaceuticals to Be Acquired by ONO Pharmaceutical in $2.4 Billion Deal (MT Newswires)
07:29AM	Deciphera Pharmaceuticals to Be Acquired by ONO Pharmaceutical in $2.4 Billion Deal (MT Newswires)
07:29AM	Deciphera to sell for $2.4B, adding to upswing in biopharma M&A (BioPharma Dive)
07:29AM	Deciphera sells for $2.4B, adding to upswing in biopharma M&A (BioPharma Dive)
07:18AM	UPDATE 2-Japan's Ono to buy US drugmaker Deciphera for $2.4 bln (Reuters)
07:06AM	Japan's ONO Pharmaceutical to buy Deciphera for $2.4 billion (Reuters)
07:00AM	Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion (Business Wire)
Apr-24-24 10:01AM	Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
10:39AM	Loading…
Apr-21-24 10:39AM	11 Best Low Price Pharma Stocks To Invest In (Insider Monkey)
Apr-09-24 07:00AM	Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum (Business Wire)
Mar-07-24 11:31AM	Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 20.8% Since Last Earnings Report? (Zacks)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Feb-28-24 09:55AM	Wall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 48.49%: Read This Before Placing a Bet (Zacks)
Feb-27-24 07:00AM	Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Feb-12-24 09:55AM	Wall Street Analysts Believe Deciphera Pharmaceuticals, Inc. (DCPH) Could Rally 59.63%: Here's is How to Trade (Zacks)
Feb-07-24 09:20AM	Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.46%
08:28AM	Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat (Zacks)
12:33AM	Q4 2023 Deciphera Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-06-24 07:00AM	Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-01-24 04:50PM	Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024 (Business Wire)
07:00AM	Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (Business Wire)
Jan-30-24 10:01AM	Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jan-18-24 11:13AM	Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (Business Wire)
Jan-08-24 07:00AM	Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company (Business Wire)
Jan-05-24 07:00AM	Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18 (Business Wire)
Jan-02-24 07:00AM	Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-15-23 07:06AM	Deciphera Pharmaceuticals CEO Steven Hoerter Sells Over 30,000 Shares (GuruFocus.com)
Dec-02-23 07:08AM	Insider Sell Alert: Daniel Martin of Deciphera Pharmaceuticals Inc Cashes Out Shares (GuruFocus.com)
Nov-29-23 11:30AM	Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 1.7% Since Last Earnings Report? (Zacks)
07:00AM	Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit (Business Wire)
Nov-07-23 07:00AM	Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Nov-01-23 03:03AM	Deciphera Pharmaceuticals Inc CEO Steven Hoerter Sells 21,573 Shares (GuruFocus.com)
Oct-31-23 07:25AM	Deciphera (DCPH) Stock Gains 17% on Q3 Earnings & Sales Beat (Zacks)
04:51AM	Q3 2023 Deciphera Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
01:16AM	The Deciphera Pharmaceuticals Inc (DCPH) Company: A Short SWOT Analysis (GuruFocus.com)
Oct-30-23 08:15AM	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +17.54%
07:01AM	Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results (Business Wire)
07:00AM	Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT (Business Wire)
Oct-16-23 12:39PM	Intellia's (NTLA) HAE Candidate Gets EMA's PRIME Designation (Zacks)
Oct-05-23 11:38AM	Deciphera Pharmaceuticals (DCPH): A Closer Look at Its Undervalued Status (GuruFocus.com)
Sep-29-23 09:00AM	Medison Pharma Announces Public Formulary Listing of QINLOCK® (ripretinib) in Canadian Provinces: Ontario and Quebec for Advanced Gastrointestinal Stromal Tumor (GIST) Treatment (PR Newswire)
Sep-22-23 12:02PM	Deciphera Pharmaceuticals Inc (DCPH): A Deep Dive into Its Performance Potential (GuruFocus.com)
11:46AM	Deciphera Pharmaceuticals (DCPH): An Intriguing Value Play with a Modestly Undervalued Market ... (GuruFocus.com)
Sep-15-23 05:00PM	Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-08-23 11:30AM	Deciphera Pharmaceuticals, Inc. (DCPH) Down 9.7% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-21-23 07:43PM	Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now (InvestorPlace)
Aug-19-23 07:40AM	3 Under-the-Radar Biotech Stocks to Buy in 2023 (Motley Fool)
Aug-18-23 04:05PM	Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-11-23 03:30PM	Why Shares of Deciphera Pharmaceuticals Rose This Week (Motley Fool)
Aug-10-23 08:13AM	Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives Revenues (Zacks) +11.50%
Aug-09-23 08:50AM	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.18%
07:00AM	Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results (Business Wire)
Aug-03-23 04:15PM	Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer (Business Wire)
Aug-02-23 07:00AM	Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023 (Business Wire)
Jun-09-23 09:02AM	Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) (Simply Wall St.)
Jun-02-23 11:31AM	Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 3.6% Since Last Earnings Report? (Zacks)
May-25-23 05:00PM	Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting (Business Wire)
May-23-23 07:00AM	Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
May-08-23 01:31PM	We're Not Very Worried About Deciphera Pharmaceuticals' (NASDAQ:DCPH) Cash Burn Rate (Simply Wall St.)
07:00AM	Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference (Business Wire)
May-04-23 05:38AM	Deciphera (DCPH) Q1 Earnings Match Estimates, Sales Miss (Zacks)
May-03-23 08:15AM	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results (Business Wire)
Apr-27-23 10:03AM	Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-26-23 10:02AM	Will Deciphera Pharmaceuticals, Inc. (DCPH) Report Negative Q1 Earnings? What You Should Know (Zacks)
07:00AM	Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023 (Business Wire)
Apr-19-23 07:00AM	Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days (Business Wire)
Apr-18-23 06:53AM	There Is A Reason Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Price Is Undemanding (Simply Wall St.)
Mar-23-23 11:30AM	Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 7% Since Last Earnings Report? (Zacks)
Mar-16-23 05:25PM	Why Deciphera Pharmaceuticals Stock Jumped This Week (Motley Fool)
Mar-15-23 11:52AM	Deciphera (DCPH) Gets Breakthrough Tag for Qinlock Expanded Use (Zacks)
06:28AM	Deciphera Pharmaceuticals (NASDAQ:DCPH) delivers shareholders stellar 103% return over 1 year, surging 15% in the last week alone (Simply Wall St.)
Mar-14-23 05:53PM	Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 (Business Wire)
05:32PM	Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023 (Business Wire)
04:26AM	Deciphera Pharmaceuticals, Inc. (DCPH) Soars 10.3%: Is Further Upside Left in the Stock? (Zacks)
Mar-09-23 11:30AM	Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Down 7.1% Since Last Earnings Report? (Zacks)
Mar-01-23 07:00AM	Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT (Business Wire)
Feb-27-23 07:00AM	Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK is Deciphera's switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kelly Thomas Patrick	Chief Financial Officer	Feb 16 '24	Sale	15.62	3,010	47,009	80,350	Feb 20 04:05 PM
Sherman Matthew L	EVP & Chief Medical Officer	Feb 16 '24	Sale	15.62	2,615	40,840	108,739	Feb 20 04:06 PM
Pitman Jama	SVP, Chief Development Officer	Feb 16 '24	Sale	15.62	2,267	35,405	68,031	Feb 20 04:05 PM
Martin Daniel C.	Chief Commercial Officer	Feb 16 '24	Sale	15.62	2,267	35,405	55,118	Feb 20 04:05 PM
Kelly Thomas Patrick	Chief Financial Officer	Jan 16 '24	Sale	14.47	2,435	35,234	66,085	Jan 18 04:15 PM
Sherman Matthew L	EVP & Chief Medical Officer	Jan 16 '24	Sale	14.47	2,435	35,234	94,079	Jan 18 04:15 PM
Pitman Jama	SVP, Chief Development Officer	Jan 16 '24	Sale	14.47	1,624	23,499	50,573	Jan 18 04:15 PM
Martin Daniel C.	Chief Commercial Officer	Jan 16 '24	Sale	14.47	1,624	23,499	47,660	Jan 18 04:15 PM
Hoerter Steven L.	President and CEO	Dec 13 '23	Sale	15.37	30,664	471,217	72,763	Dec 14 04:05 PM
Kelly Thomas Patrick	Chief Financial Officer	Dec 13 '23	Sale	15.37	2,792	42,905	68,520	Dec 14 04:05 PM
Sherman Matthew L	EVP & Chief Medical Officer	Dec 13 '23	Sale	15.37	2,792	42,905	96,514	Dec 14 04:05 PM
Martin Daniel C.	Chief Commercial Officer	Dec 13 '23	Sale	15.37	1,727	26,539	49,284	Dec 14 04:05 PM
Pitman Jama	See Remarks	Dec 13 '23	Sale	15.37	1,662	25,540	52,197	Dec 14 04:05 PM
Martin Daniel C.	Chief Commercial Officer	Nov 30 '23	Sale	12.57	17,801	223,755	45,435	Dec 01 04:05 PM
Hoerter Steven L.	President and CEO	Oct 30 '23	Sale	12.02	21,573	259,256	40,927	Oct 31 04:09 PM
Sherman Matthew L	EVP & Chief Medical Officer	Oct 30 '23	Sale	12.02	2,360	28,362	90,628	Oct 31 04:11 PM
Kelly Thomas Patrick	Chief Financial Officer	Oct 30 '23	Sale	12.02	2,316	27,833	63,068	Oct 31 04:09 PM
Martin Daniel C.	Chief Commercial Officer	Oct 30 '23	Sale	12.02	1,407	16,909	62,884	Oct 31 04:10 PM
Pitman Jama	See Remarks	Oct 30 '23	Sale	12.02	1,407	16,909	48,283	Oct 31 04:10 PM
Sherman Matthew L	EVP & Chief Medical Officer	Oct 02 '23	Sale	12.68	2,942	37,305	84,744	Oct 04 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DCPH

Deciphera Pharmaceuticals Inc

Upgrade your FINVIZ experience